Pfizer Ltd shareholders approved the audited financial statements for the fiscal year ended March 31, 2026, and received a Rs. 75 per share dividend. The company's 75th AGM also saw the re-appointment of a director and ratification of cost auditor remuneration.
Detailed Coverage
Pfizer Ltd Approves Rs. 75 Dividend at 75th AGM
Rs. 75 per share dividend declared; FY26 audited financials adopted.
Reader Takeaway: Rs. 75 dividend payout; clean audit reports offer shareholder assurance.
What just happened
Pfizer Limited held its 75th Annual General Meeting (AGM) virtually on July 28, 2026. During the meeting, shareholders adopted the audited financial statements for the fiscal year ending March 31, 2026. A key resolution approved was the declaration of a dividend of Rs. 75 per equity share (750%).
Why this matters
The dividend declaration provides a direct financial return to shareholders. The adoption of audited financials and the absence of any qualifications or adverse remarks in the auditors' reports signal strong corporate governance and financial transparency for the fiscal year 2026.
The backstory
This AGM marks the 75th such meeting for Pfizer Ltd. The company has a long-standing presence in India, manufacturing and marketing a range of pharmaceutical products. The event is a standard annual corporate compliance requirement where shareholders vote on key company matters and financial performance.
What changes now
Shareholders who held eligible shares will receive the declared dividend of Rs. 75 per share. The re-appointment of Mr. P. Rengan as Director and the ratification of the cost auditor's remuneration solidify the company's operational and governance structure for the upcoming financial year.
Risks to watch
While the filing details standard corporate procedures, potential risks for investors could include future dividend policies, market competition affecting product performance, and regulatory changes impacting the pharmaceutical sector in India.
Peer comparison
Pfizer Ltd operates in the highly competitive Indian pharmaceutical market. Dividend payouts and financial performance are key metrics compared against peers like GlaxoSmithKline Pharmaceuticals, Abbott India, and Cipla. Consistency in dividend distribution and strong financial health are crucial for investor confidence.
Context metrics (time-bound)
- Dividend: Rs. 75 per equity share (750%) for the fiscal year ended March 31, 2026.
- AGM Date: July 28, 2026.
- Fiscal Year Reviewed: Ended March 31, 2026.
- Cost Auditor Remuneration: Ratified for the financial year ending March 31, 2027.
What to track next
Investors should track the official disclosure of e-voting results within two working days. Future performance updates, new product launches, and the company's ESG initiatives will be key indicators to monitor.
